{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:05:02Z","timestamp":1784909102810,"version":"3.55.0"},"reference-count":66,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007229","name":"Harvard University","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100007229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Ratiometric delivery of combination chemotherapy can achieve therapeutic efficacy based on synergistic interactions between drugs. It is critical to design such combinations with drugs that complement each other and reduce cancer growth through multiple mechanisms. Using hyaluronic acid (HA) as a carrier, two chemotherapeutic agents\u2014doxorubicin (DOX) and camptothecin (CPT)\u2014were incorporated and tested for their synergistic potency against a broad panel of blood-cancer cell lines. The pair also demonstrated the ability to achieve immunogenic cell death by increasing the surface exposure levels of Calreticulin, thereby highlighting its ability to induce apoptosis via an alternate pathway. Global proteomic profiling of cancer cells treated with HA\u2013DOX\u2013CPT identified pathways that could potentially predict patient sensitivity to HA\u2013DOX\u2013CPT. This lays the foundation for further exploration of integrating drug delivery and proteomics in personalized immunogenic chemotherapy.<\/jats:p>","DOI":"10.3390\/pharmaceutics14020466","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:47:45Z","timestamp":1645476465000},"page":"466","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Hyaluronic Acid Nanoparticles for Immunogenic Chemotherapy of Leukemia and T-Cell Lymphoma"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0098-7864","authenticated-orcid":false,"given":"Vinu","family":"Krishnan","sequence":"first","affiliation":[{"name":"School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA"},{"name":"Wyss Institute of Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimisha","family":"Dharamdasani","sequence":"additional","affiliation":[{"name":"School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA"},{"name":"Wyss Institute of Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Bakre","sequence":"additional","affiliation":[{"name":"School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ved","family":"Dhole","sequence":"additional","affiliation":[{"name":"School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA"},{"name":"Wyss Institute of Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-2003","authenticated-orcid":false,"given":"Bogdan","family":"Budnik","sequence":"additional","affiliation":[{"name":"Mass Spectrometry Proteomics and Research Laboratory, FAS Division of Science, Harvard University, Cambridge, MA 02138, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Mitragotri","sequence":"additional","affiliation":[{"name":"School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA"},{"name":"Wyss Institute of Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1349-7006.2008.00768.x","article-title":"Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)\/T-cell lymphoma and leukemia","volume":"99","author":"Yamaguchi","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_2","first-page":"CD003372","article-title":"Single agent versus combination chemotherapy for metastatic breast cancer","volume":"2021","author":"Carrick","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1200\/JCO.2011.37.6418","article-title":"Development of therapeutic combinations targeting major cancer signaling pathways","volume":"31","author":"Yap","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12185-015-1809-x","article-title":"High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed\/refractory extranodal natural killer\/T cell lymphoma: A retrospective study","volume":"102","author":"Ding","year":"2015","journal-title":"Int. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/hon.2325","article-title":"A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer\/T-cell lymphoma, nasal type: A multicenter trial in Northwest China","volume":"35","author":"Liang","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.10.011","article-title":"A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer\/T-Cell Lymphoma, Nasal-Type","volume":"25","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000508658","article-title":"Sustained Complete Remission with Incomplete Hematologic Recovery (CRi) in a Patient with Relapsed AML and Concurrent BCR-ABL1 and CBFB Rearrangement Treated with a Combination of Venetoclax and 5-Azacytidine","volume":"65","author":"Levato","year":"2020","journal-title":"Chemotherapy"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/17474086.2020.1796620","article-title":"The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia","volume":"13","author":"Vitale","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1021\/mp800240j","article-title":"Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells","volume":"6","author":"Ganta","year":"2009","journal-title":"Mol. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"137414","DOI":"10.1155\/2013\/137414","article-title":"Drug resistance and the role of combination chemotherapy in improving patient outcomes","volume":"2013","author":"Yardley","year":"2013","journal-title":"Int. J. Breast Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/ijc.30262","article-title":"Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013","volume":"139","author":"Nikanjam","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"84559","DOI":"10.18632\/oncotarget.19187","article-title":"Novel strategies to prevent the development of multidrug resistance (MDR) in cancer","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e50036","DOI":"10.7554\/eLife.50036","article-title":"A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity","volume":"8","author":"Palmer","year":"2019","journal-title":"Elife"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3747\/co.v16i2.420","article-title":"Metronomic chemotherapy: Changing the paradigm that more is better","volume":"16","author":"Scharovsky","year":"2009","journal-title":"Curr. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1021\/mp800049w","article-title":"Pharmacokinetics and biodistribution of nanoparticles","volume":"5","author":"Li","year":"2008","journal-title":"Mol. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.molmed.2015.01.001","article-title":"Cancer nanomedicine: From targeted delivery to combination therapy","volume":"21","author":"Xu","year":"2015","journal-title":"Trends Mol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.2174\/1381612821666150531165059","article-title":"Nanoparticle-Based Combination Therapy for Cancer Treatment","volume":"21","author":"Yhee","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Li, L., He, H., Jiang, S., Qi, J., Lu, Y., Ding, N., Lin, H.S., Wu, W., and Xiang, X. (2021). Simulation of the In Vivo Fate of Polymeric Nanoparticles Traced by Environment-Responsive Near-Infrared Dye: A Physiologically Based Pharmacokinetic Modelling Approach. Molecules, 26.","DOI":"10.3390\/molecules26051271"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"33850","DOI":"10.1021\/acsami.1c07739","article-title":"Biocompatible Superparamagnetic Europium-Doped Iron Oxide Nanoparticle Clusters as Multifunctional Nanoprobes for Multimodal In Vivo Imaging","volume":"13","author":"Zhang","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Fatima, I., Rahdar, A., Sargazi, S., Barani, M., Hassanisaadi, M., and Thakur, V.K. (2021). Quantum Dots: Synthesis, Antibody Conjugation, and HER2-Receptor Targeting for Breast Cancer Therapy. J. Funct. Biomater., 12.","DOI":"10.3390\/jfb12040075"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2015.04.031","article-title":"Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid","volume":"210","author":"Camacho","year":"2015","journal-title":"J. Control Release"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jconrel.2017.08.016","article-title":"A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer","volume":"267","author":"Vogus","year":"2017","journal-title":"J. Control Release"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"eabe6627","DOI":"10.1126\/sciadv.abe6627","article-title":"Hyaluronic acid conjugates for topical treatment of skin cancer lesions","volume":"7","author":"Krishnan","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/jcp.56.10.747","article-title":"Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: A tissue microarray analysis of 90 cases","volume":"56","author":"Tzankov","year":"2003","journal-title":"J. Clin. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/leu.2010.281","article-title":"High levels of the adhesion molecule CD44 on leukemic cells generate acute myeloid leukemia relapse after withdrawal of the initial transforming event","volume":"25","author":"Quere","year":"2011","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1021\/mp800024g","article-title":"Anticancer therapeutics: Targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor","volume":"5","author":"Platt","year":"2008","journal-title":"Mol. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/08982100500364081","article-title":"6-mercaptopurine and daunorubicin double drug liposomes-preparation, drug-drug interaction and characterization","volume":"15","author":"Agrawal","year":"2005","journal-title":"J. Liposome Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3727\/000000006783980937","article-title":"Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios","volume":"16","author":"Harasym","year":"2007","journal-title":"Oncol. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/cmdc.200700121","article-title":"Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates","volume":"2","author":"Zhang","year":"2007","journal-title":"ChemMedChem"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1016\/j.biomaterials.2009.02.040","article-title":"Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers","volume":"30","author":"Lammers","year":"2009","journal-title":"Biomaterials"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1080\/10611860802473154","article-title":"Surface-engineered dendrimers for dual drug delivery: A receptor up-regulation and enhanced cancer targeting strategy","volume":"16","author":"Tekade","year":"2008","journal-title":"J. Drug Target"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc1565","article-title":"The promise of genetically engineered mice for cancer prevention studies","volume":"5","author":"Green","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2006-10-054221","article-title":"Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: Therapeutic implications","volume":"109","author":"Spisek","year":"2007","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e28473","DOI":"10.4161\/onci.28473","article-title":"Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set","volume":"3","author":"Sukkurwala","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/10799893.2019.1655050","article-title":"Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma","volume":"39","author":"Sun","year":"2019","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.canlet.2019.11.025","article-title":"Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models","volume":"470","author":"Du","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2005.02.509","article-title":"Mapping molecular networks using proteomics: A vision for patient-tailored combination therapy","volume":"23","author":"Petricoin","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/bioinformatics\/btx766","article-title":"Global proteomics profiling improves drug sensitivity prediction: Results from a multi-omics, pan-cancer modeling approach","volume":"34","author":"Ali","year":"2018","journal-title":"Bioinformatics"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e1800087","DOI":"10.1002\/prca.201800087","article-title":"Proteomics in Drug Development: The Dawn of a New Era?","volume":"13","author":"Frantzi","year":"2019","journal-title":"Proteomics Clin. Appl."},{"key":"ref_41","first-page":"2350","article-title":"Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: Did we miss something in CPT analogue molecular targets for treating human disease such as cancer?","volume":"7","author":"Li","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1039\/C9BM00425D","article-title":"GSH\/pH dual-responsive biodegradable camptothecin polymeric prodrugs combined with doxorubicin for synergistic anticancer efficiency","volume":"7","author":"Li","year":"2019","journal-title":"Biomater. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/anie.201812650","article-title":"Treating Tumors at Low Drug Doses Using an Aptamer-Peptide Synergistic Drug Conjugate","volume":"58","author":"Pusuluri","year":"2019","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00685553","article-title":"Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors","volume":"31","author":"Houghton","year":"1992","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_45","first-page":"539","article-title":"Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy","volume":"54","author":"Husain","year":"1994","journal-title":"Cancer Res."},{"key":"ref_46","first-page":"17","article-title":"Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies","volume":"8","author":"Bronstein","year":"1996","journal-title":"Oncol. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00000421-200006000-00019","article-title":"A phase I study of liposomal doxorubicin (Doxil) with topotecan","volume":"23","author":"Ryan","year":"2000","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/07357900500359877","article-title":"Phase I clinical trial of topotecan and pegylated liposomal doxorubicin","volume":"23","author":"Garcia","year":"2005","journal-title":"Cancer Invest."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1158\/1078-0432.CCR-04-1240","article-title":"Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer","volume":"11","author":"Mirchandani","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1525-1438.2006.00728.x","article-title":"Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: Interim analysis","volume":"17","author":"Nishimura","year":"2007","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/COC.0b013e318168ef2a","article-title":"A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies","volume":"31","author":"Goff","year":"2008","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000264925","article-title":"A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors","volume":"55","author":"Morgensztern","year":"2009","journal-title":"Chemotherapy"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00280-014-2418-8","article-title":"A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)","volume":"73","author":"Shoji","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nmeth.1322","article-title":"Universal sample preparation method for proteome analysis","volume":"6","author":"Wisniewski","year":"2009","journal-title":"Nat. Methods"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"i42","DOI":"10.1093\/bioinformatics\/btn294","article-title":"Non-parametric estimation of posterior error probabilities associated with peptides identified by tandem mass spectrometry","volume":"24","author":"Kall","year":"2008","journal-title":"Bioinformatics"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Pandya, U.M., Egbuta, C., Abdullah Norman, T.M., Chiang, C.E., Wiersma, V.R., Panchal, R.G., Bremer, E., Eggleton, P., and Gold, L.I. (2019). The Biophysical Interaction of the Danger-Associated Molecular Pattern (DAMP) Calreticulin with the Pattern-Associated Molecular Pattern (PAMP) Lipopolysaccharide. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20020408"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Solari, J.I.G., Filippi-Chiela, E., Pilar, E.S., Nunes, V., Gonzalez, E.A., Figueiro, F., Andrade, C.F., and Klamt, F. (2020). Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06964-5"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1158\/0008-5472.CAN-11-0950","article-title":"Human tumor cells killed by anthracyclines induce a tumor-specific immune response","volume":"71","author":"Fucikova","year":"2011","journal-title":"Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.3892\/ol.2016.4175","article-title":"Dendritic cells combined with doxorubicin induces immunogenic cell death and exhibits antitumor effects for osteosarcoma","volume":"11","author":"Kawano","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_61","first-page":"151","article-title":"Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma","volume":"39","author":"Aoto","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/bbrc.1996.0373","article-title":"HSP70 overexpression mediates the escape of a doxorubicin-induced G2 cell cycle arrest","volume":"220","author":"Karlseder","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s12192-016-0730-4","article-title":"Targeting HSP70 and GRP78 in canine osteosarcoma cells in combination with doxorubicin chemotherapy","volume":"21","author":"Asling","year":"2016","journal-title":"Cell Stress Chaperones"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11010-018-3469-7","article-title":"The increased expression of the inducible Hsp70 (HSP70A1A) in serum of patients with heart failure and its protective effect against the cardiotoxic agent doxorubicin","volume":"455","author":"Zerikiotis","year":"2019","journal-title":"Mol. Cell. Biochem."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Dastsooz, H., Cereda, M., Donna, D., and Oliviero, S. (2019). A Comprehensive Bioinformatics Analysis of UBE2C in Cancers. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092228"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Vargas-Rondon, N., Villegas, V.E., and Rondon-Lagos, M. (2017). The Role of Chromosomal Instability in Cancer and Therapeutic Responses. Cancers, 10.","DOI":"10.3390\/cancers10010004"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/2\/466\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:24:07Z","timestamp":1760135047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/2\/466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":66,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["pharmaceutics14020466"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14020466","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]}}}